5.0 REFERENCES:

5. USFDA Guidelines-21 CFR Part 320 Bioequivalence and bioavailability requirements, section 320.1Definitions.
6. USFDA Guidelines-21 CFR Part 320 Bioequivalence and bioavailability requirements, section 320.23 Basis for measuring in vivo bioavailability or demonstrating bioequivalence.
17. Multisource (GENERIC) pharmaceutical products: guidelines on registration requirements to establish interchangeability, WHO (2005), Revision 04.
24. Epilepsy Foundation of America Inc., Centre for Disease Control and Prevention (Grant No. 5U58DP00606-03, 2009).


40. Monica Whitmire, Jennifer Ammerman, Patricia de Lisio, Jacqueline Killmer, Devon Kyle, Emily Mainstone, Lynann Porter and Tianyi Zhang (2011), LC-MS/MS Bioanalysis Method Development, Validation, and Sample Analysis: Points to Consider When Conducting Nonclinical and Clinical Studies in


50. ICH guideline M3 (R2) on non-clinical safety studies for the conduct of human clinical trials and marketing authorisation for pharmaceuticals; Step 5 (2009).


57. E. J. Williams (1948), Experimental designs balanced for the residual effects of treatment, Australian Journal of Scientific Research, 2, 149-168.
60. Kelly KM (1998), Gabapentin: antiepileptic mechanism of action, Neuropsychobiology, 38, 139-144.
receptors with specific heterodimer composition and postsynaptic actions in hippocampal neurons are targets of anticonvulsant gabapentin action, Mol Pharmacol, 59, 144-152.


70. Surges R, Freiman TM, Feuerstein TJ (2003), Gabapentin increases the hyperpolarization-activated cation current Ih in rat CA1 pyramidal cells, Epilepsia, 44, 150-156.


76. Toufigh Gordi, Eddie Hou, Sreeneeran Kasichayanula and Bret Berner (2008), Pharmacokinetics of Gabapentin After a Single Day and at Steady State Following the Administration of Gastric-Retentive–Extended-Release
and Immediate-Release Tablets: A Randomized, Open-Label, Multiple-Dose, Three-Way Crossover, Exploratory Study in Healthy Subjects, Clinical Therapeutics/Volume 30.


79. Dan Chen, MD, Ritu Lal, Katie Zomorodi, Harisha Atluri, Judy Ho, Wendy Luo, James Tovera, Daniel Bonzo, and Kenneth Cundy (2012), Evaluation of Gabapentin Enacarbil on Cardiac Repolarization: A Randomized, Double-Blind, Placebo- and Active-Controlled, Crossover Thorough QT/QTc Study in Healthy Adults, Clinical Therapeutics/Volume 34.


81. Dwayne A. Pierce, PharmD1; Shea R. Holt, MD2; and Amber Reeves-Daniel, DO 2 (2008), A probable cause of Gabapentin related reversible Hearing Loss in a patient with Acute Renal failure, Clinical Therapeutics/Volume 30.


103. L.Z. Benet (1999), Understanding Bioequivalence Testing, Transplantation Proceedings, 31 (Suppl 3A), 7S–9S.

104. Herman P. Wijnand ((1994), Updates of bioequivalence programs (including statistical power approximated by Student's t), Computer Methods and Programs in Biomedicine, 42, 275-281.


106. Peter Meredith, PhD (2003), Bioequivalence and Other Unresolved Issues in Generic Drug Substitution, Clinical Therapeutics, Vol. 25, No. 11.


